Evaluation of Relationship between Minimal Residual Disease (MRD) and Relapse in Childhood Acute Lymphoblastic Leukemia (ALL) Using Quantitative Fluorescent PCR

evaluation of relationship between minimal residual disease (mrd) and relapse in childhood acute lymphoblastic leukemia (all) using quantitative fluorescent pcr

0

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)

The amplification of putative oncogenes is a common finding within the genome of various cancer types. Identification and further targeting of specific junction sites within the sequence of genomic amplicons (amplicon fusion sites, AFS) by PCR (AFS-PCR) is suitable for quantification of minimal residual disease (MRD). This approach has recently been developed and described for MYCN amplified ne...

flowcytometric and dna analysis minimal residual disease (mrd) in childhood b-lineage lymphoblastic leukemia

background: induction chemotherapy for acute lymphoblastic leukemia achieves complete remis sion in over 90% of children. it is apparent therefore that many patients in clinical remission and with out residual disease detectable by conventional light microscopy of peripheral blood or bone marrow films still harbor viable cells of the original disease mrd analysis does have a useful role to play...

Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

The relation between end of induction minimal residual disease and different risk factors in patients with acute lymphoblastic leukemia

Background: Malignant disorder with B or T stem cell basis leads to development and continuation of acute lymphoblastic leukemia (ALL) due to aggregation of blast cells in bone marrow. The environmental, genetic, and demographic factors may influence the disease relapse. The objective of this study was to assess the relation between end of induction minimal residual disease and different risk f...

Minimal residual disease in acute lymphoblastic leukemia.

In patients with acute lymphoblastic leukemia (ALL), monitoring of minimal residual disease (MRD) offers a way to precisely assess early treatment response and detect relapse. Established methods to study MRD are flow cytometric detection of abnormal immunophenotypes, polymerase chain reaction (PCR) amplification of antigen-receptor genes, and PCR amplification of fusion transcripts. The strong...